News & Comment

Filter by:

  • Better data for better insights and improved outcomes—Molecular Health has built one of the largest, deepest and fully curated digital platforms for biomedicine in the world. The company’s ‘Dataome’ provides the foundation for actionable insights for stakeholders across the healthcare ecosystem.

    • Molecular Health GmbH
    Advertisement Feature
  • Auransa’s AI-driven prediction of drug candidates and corresponding patient responders increases the chances of clinical trial success.

    • Auransa Inc.
    Advertisement Feature
  • Deep Quartet, a drug discovery platform developed by INTAGE Healthcare and the Institute for Theoretical Medicine (ITM) uses AI technologies to design new lead compound structures based on pharmacophore models.

    • INTAGE Healthcare
    Advertisement Feature
  • Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

    • Raveena Bhambra
    News Feature
  • Vincerx applies a modular approach in the development of antibody–drug conjugates by incorporating novel targeting and safety features. The company’s lead compounds exhibit high efficacies with minimal toxicities that are expected to improve therapeutic windows. Vincerx believes that partners with first-in-class antibodies, clinical stage antibodies or ADCs against promising targets will benefit from Vincerx’s next-generation payload-linker technologies.

    • Vincerx Pharma
    Advertisement Feature
  • Gene therapy company FerGene Inc. is developing products for the treatment of urologic cancers, the company’s lead product, nadofaragene firadenovec, uses a non-replicating adenovirus vector to deliver the gene for interferon alfa-2b into bladder cells for the treatment of bladder cancer.

    • FerGene Inc.
    Advertisement Feature
  • With its plug-and-play cell therapy platform and complementary bispecific NK cell engagers, Cytovia aims to create both single and combination therapies for cancer treatment.

    • Cytovia Therapeutics
    Advertisement Feature
  • Amarna Therapeutics has developed SVec, a non-immunogenic viral vector platform for the development of candidates to treat genetic and autoimmune disorders, overcoming immune barriers to gene therapy delivery and unlocking autoimmunity by inducing tolerance.

    • Amarna Therapeutics BV
    Advertisement Feature
  • Sutro Biopharma combines its powerful cell-free protein synthesis platform with click chemistry to develop precisely engineered bioconjugate therapeutics for oncology.

    • Sutro Biopharma
    Advertisement Feature
  • A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.

    • John Hodgson
    News Feature
  • Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative mechanism to existing cancer immunotherapy strategies. PT-112, Phosplatin’s lead ICD inducer, is in phase 2 clinical trials for metastatic castration-resistant prostate cancer, and could be applicable to other indications, including rare and refractory forms of cancer.

    • Phosplatin Therapeutics
    Advertisement Feature
  • Cellestia Biotech AG is developing first-in-class therapies to control pathogenic gene expression by selective inhibition of previously undruggable transcription factors in the cell nucleus. The company’s clinical lead, CB-103, has advanced to phase 2 in oncology, followed by a rich R&D pipeline of novel gene transcription factor inhibitors targeting oncology, autoimmune and inflammatory disorders.

    • Cellestia Biotech AG
    Advertisement Feature
  • Biotech company Fibriant has developed a unique recombinant fibrinogen manufacturing platform that is able to create a range of products that offer advantages over the plasma version.

    • Fibriant BV
    Advertisement Feature
  • After a slow start due to the COVID-19 pandemic, oncology dealmaking thrived in 2020 as immuno-oncology fueled a number of high-value drug licensing deals and a string of billion-dollar M&As were announced.

    • Sarah Hardison
    News Feature
  • Biotechnology company BioTheryX develops unique therapeutics for both oncology and inflammatory diseases based upon its novel protein degradation technology platform.

    • BioTheryX
    Advertisement Feature